An Improved Method for Developing Injury Risk Curves Using the Brier Metric Score
Related Experiment Video
Updated: Nov 29, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Zachary S Hostetler1, Fang-Chi Hsu2, Narayan Yoganandan3
1Biomedical Engineering, Wake Forest School of Medicine, 575 N. Patterson Avenue, Winston-Salem, NC, 27101, USA.
Abstract:
Many injury metrics are routinely proposed from measured or derived quantities from biomechanical experiments using post mortem human subjects (PMHS). The existing literature did not provide guidance on deciding between parameters collected in an experiment that would be best to use for the development of human injury probability curves (HIPC). The objective of this study was to use the Brier Metric Score (BMS) to identify the most appropriate metric from an experiment that predicts injury outcomes. The Brier Metric Score assesses how well a metric predicts the outcome for a censored data point (a lower BMS is better). Survival analysis was then conducted with the selected metric and the best distribution was selected using Akaike information criterion (AIC). Confidence intervals (CIs) and the normalized confidence interval width (NCIS) were calculated for the injury probability curve. The testing and validation of the methods described were performed using biomechanics data in the open literature. The methods for the HIPC development procedure detailed herein have been rigorously tested and used in the generation of WIAMan HIPCs and Injury Assessment Reference Curves (IARCs) for the WIAMan ATD, but can also be used in other ATD or PMHS injury risk curve development.
Related Concept Videos
Relative Risk
z Scores and Area Under the Curve
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Kaplan-Meier Approach
Hazard Ratio
For example, in a clinical trial...

